Skip to NavigationSkip to content

Johnson & Johnson

Celgene bring in new CFO to steady the ship

The fact that Celgene is currently sailing through choppy waters is no secret to anyone within the industry, it’s facing serious questions over its pipeline and major worries about its lead candidate, ozanimod.

Behind this drama has been a steadily revolving door of executive exits from the company, as it attempts to display to its shareholders that it is taking a fresh approach to business. It needs to demonstrate this if it is to shore up its share price, which is significantly down from where it stood in October last year ($146 down to $79, at present).

J&J terminates PD-(L)1 combo studies of cancer therapy Darzalex

Johnson & Johnson is to terminate its studies investigating Genmab’s CD38-targeting, human IgG1κ monoclonal antibody Darzalex (daratumumab) in combination with Roche’s PD-L1 inhibitor Tecentriq (atezolizumab) in patients with previously treated non-small cell lung cancer.

J&J's ketamine-based antidepressant showed mixed success at Phase 3

Johnson & Johnson has revealed new data on its new depression drug esketamine, its chemically ‘left-handed’ version of the controlled anaesthetic often used recreationally, painting a mixed picture of its efficacy.

J&J’s ketamine nasal spray for depression continues to impress

New treatments for depression are few and far between; pharmaceutical companies have shied away from trying to develop new therapeutics due to the difficulty in overcoming the placebo effect in treating depression.

This is possibly why researchers and companies are now looking to existing compounds, which have previously not been investigated due to their reputation as party drugs.

Working Life: Kris Sterkens, Company Group Chairman, Janssen EMEA

Published on 12/04/18 at 10:11am sat down with Kris Sterkens, Company Group Chairman of Janssen's EMEA operations to discuss nearly three decades at the company, and what continues to drive his work.

How did your father’s profession as a physician and your early life influence the career path you eventually chose?

J&J pays out $37m in damages over claims its talc contains asbestos

Bad news for Johnson & Johnson as it emerges that the US pharma giant has been ordered to pay out $37 million in damages after losing the first trial in a legal dispute which alleges that its Baby Powder product contains the carcinogenic ingredient asbestos.

J&J’s longest-standing CFO finally steps down

Johnson & Johnson have revealed that its Chief Financial Officer and Executive Vice President, Dominic J. Caruso, will retire from his position in September of this year.

Caruso spent close to 12 years in his position as CFO of the pharma giant and was the longest serving in this position during the company’s 132-year history.

FDA expands J&J Zytiga combo's indication to include castration-sensitive prostate cancer

Johnson & Johnson has announced that Zytiga (abiraterone acetate) in combination with prednisone has been awarded FDA approval in the treatment of metastatic high-risk castration-sensitive prostate cancer (CSPC).

Theravance seals potential $1bn deal with J&J

The JAK inhibitor field is beginning to heat up – AbbVie is soon to enter Phase 3 with its predicted best-in-class therapy, Gilead is working with Galapagos on a potential rival and Celgene started the year off with a $1.1 billion upfront deal for Impact Biomedicine, gaining them access to its JAK2 inhibitor.

J&J's apalutamide shows strength in non-metastatic prostate cancer

Johnson & Johnson unveiled new data at the ASCO Genitourinary Cancer symposium which demonstrated that its androgen receptor antagonist apalutamide significantly improved median metastasis-free survival (MFS) by two years compared to placebo in patients with non-metastatic castration-resistant prostate cancer (nmCRPC).

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches